Status:
UNKNOWN
A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy
Lead Sponsor:
Kagawa University
Conditions:
Glomerulonephritis, IGA
Hypertension
Eligibility:
All Genders
16-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the effect of aliskiren, a novel direct rennin inhibitor, on renal function and progress of renal disease in hypertensive patients with IgA nephropathy.
Eligibility Criteria
Inclusion
- IgA nephropathy confirmed by renal biopsy
- Hypertension (\<= 125/75 mmHg)
Exclusion
- Patients who have been treated with angiotensin type 1 receptor blocker or angiotensin-converting enzyme inhibitor within 4 weeks
- Severe hypertension (\<= 180/110 mmHg) or secondary hypertension
- Patients with history of allergy or adverse effect for aliskiren
- Renal dysfunction (estimated Glomerular Filtration Rate \< 60 mL/min/1.73m2)
- Pregnancy
- Patient treated with cyclosporine
- Hyperkalemia (serum potassium \>= 5.6 mmol/L)
- Autoimmune disease including systemic lupus erythematosus
- Patients inadequate for the study
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01184599
Start Date
June 1 2010
Last Update
June 27 2011
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Kurume University, School of Medicine
Fukuoka, Japan, 830-0011
2
Department of Internal Medicine, Osaka City General Hospital
Osaka, Japan, 534-0021
3
Ohno memorial Hospital
Osaka, Japan, 550-0015
4
Kinki University, Faculty of Medicine
Osaka, Japan, 589-8511